Source:http://linkedlifedata.com/resource/pubmed/id/17290447
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
2007-6-27
|
pubmed:abstractText |
A genetic variation in fatty acid amide hydrolase (FAAH), C385A (P129T), has been previously associated with risk for problem street drug use. FAAH is a mammalian enzyme that inactivates neuromodulatory-signaling lipids including the endogenous cannabinoid 1 receptor agonist anandamide. We investigated in adult Caucasians (N = 749) whether this FAAH variant altered the risk for trying, regular use of or dependence on cannabis, alcohol or nicotine, traditional "gateway" drugs. Consistent with our knowledge that the A/A genotype results in reduced FAAH expression and activity in humans, subjects with the A/A genotype were less likely to be THC dependent than subjects with either a C/C or C/A genotype (11% vs. 26%, P < 0.05). No association was observed between the A/A genotype and risk for alcohol or tobacco regular use, or DSM IV dependence. Controlling for regular use of nicotine and sedatives, both identified as confounders, those with the A/A genotype were at significantly reduced risk for being THC dependent (OR 0.25, 95% CI: 0.07-0.88) as compared with those with the C/A or C/C genotype, supporting a link between alterations in the endocannabinoid system and THC dependence. Unexpectedly, we found an increased risk for regular use of sedatives among the A/A genotype group. The relationship between the FAAH A/A genotype and risk for drug dependence in this study was drug class specific, suggesting it is not part of a more general drug abuse effect. These results, particularly the observation of altered risk for sedative drug use, should be investigated further in multiple ethnic populations.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
1552-4841
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
5
|
pubmed:volume |
144B
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
660-6
|
pubmed:dateRevised |
2008-5-21
|
pubmed:meshHeading |
pubmed-meshheading:17290447-Adult,
pubmed-meshheading:17290447-Alcohol Drinking,
pubmed-meshheading:17290447-Amidohydrolases,
pubmed-meshheading:17290447-Canada,
pubmed-meshheading:17290447-Cannabinoids,
pubmed-meshheading:17290447-Female,
pubmed-meshheading:17290447-Genetic Predisposition to Disease,
pubmed-meshheading:17290447-Genotype,
pubmed-meshheading:17290447-Humans,
pubmed-meshheading:17290447-Logistic Models,
pubmed-meshheading:17290447-Male,
pubmed-meshheading:17290447-Marijuana Smoking,
pubmed-meshheading:17290447-Mutation, Missense,
pubmed-meshheading:17290447-Smoking,
pubmed-meshheading:17290447-Substance-Related Disorders
|
pubmed:year |
2007
|
pubmed:articleTitle |
The fatty acid amide hydrolase C385A (P129T) missense variant in cannabis users: studies of drug use and dependence in Caucasians.
|
pubmed:affiliation |
Department of Pharmacology, Centre for Addiction and Mental Health, University of Toronto, Ontario, Canada.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|